Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Gastric Cancer

Presenters

Rui-Hua Xu

Citation

Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422

Authors

R. Xu1, Z. Dongsheng1, J. Ajani2, S. Al-Batran3, Y. Bang4, D. Catenacci5, P. Enzinger6, D. Ilson7, S. Kim8, F. Lordick9, K. Shitara10, E. Van Cutsem11, A. Arozullah12, J. Wook Park12, M. Shah13

Author affiliations

  • 1 Medical Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Department Of Gastrointestinal Medical Oncology, Division Of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Institute Of Clinical Cancer Research, Institut für Klinisch-Onkologische Forschung, Frankfurt/DE
  • 4 Medical Oncology, Seoul National University Hospital, Seoul/KR
  • 5 Gastrointestinal Oncology Program, University of Chicago, Chicago/US
  • 6 Medical Oncology, 6Center for Esophageal and Gastric Cancer, Dana-Farber Cancer Institute, Boston/US
  • 7 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City/US
  • 8 Hematology Oncology, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington/US
  • 9 University Cancer Center Leipzig, University of Leipzig, 04103 - Leipzig/DE
  • 10 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East Kashiwa City, 277-8577 - Chiba/JP
  • 11 Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven/BE
  • 12 ., Astellas Pharma Global Development, Inc., Northbrook/US
  • 13 Medical Oncology, Weill Cornell Medical College, New York City/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 197TiP

Background

Gastric cancer (GC) is the fourth leading cause of cancer death worldwide, with disproportionate incidence and mortality rates reported for people from Eastern Asia. Capecitabine + oxaliplatin (CAPOX) is a standard first-line treatment for advanced GC. Recently, Claudin (CLDN)18.2 has emerged as a promising targetable biomarker. In healthy tissue, CLDN18.2 is confined to gastric mucosa tight junctions. Upon malignant transformation, cell polarity perturbations lead to exposure of CLDN18.2 on the cell surface. Zolbetuximab is a chimeric IgG1 monoclonal antibody that specifically binds to CLDN18.2 and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. In a randomized phase 2 study (NCT01630083), patients with CLDN18.2+ advanced GC/GEJ treated with zolbetuximab + epirubicin, oxaliplatin, and capecitabine (EOX) showed prolonged survival compared with EOX alone.

Trial design

This phase 3, double-blind, placebo-controlled study (NCT03653507) will enroll ∼500 adult patients from global sites, including sites in China, Japan, Republic of Korea, and Thailand. Patients with CLDN18.2+/HER2 locally advanced unresectable or metastatic GC or GEJ not previously treated with chemotherapy will be eligible. Patients will be randomized 1:1 to receive zolbetuximab + CAPOX or placebo + CAPOX. Zolbetuximab will be administered as an 800-mg/m2 IV loading dose followed by 600 mg/m2 Q3W in combination with CAPOX. Central testing of tumor tissue will determine CLDN18.2 and HER2 status (if unknown); patients will be considered CLDN18.2+if ≥ 75% of tumor cells demonstrate moderate-to-strong membranous IHC staining. The primary objective is to compare progression-free survival of zolbetuximab + CAPOX vs placebo + CAPOX. The key secondary efficacy endpoint is overall survival. Objective response rate, duration of response, the safety/tolerability profile, PK profile, and immunogenicity of zolbetuximab are other secondary endpoints.

Clinical trial identification

NCT03653507.

Legal entity responsible for the study

Astellas Pharma US, Inc.

Funding

Astellas Pharma US, Inc.

Disclosure

J. Ajani: Advisory / Consultancy, Research grant / Funding (institution): Astellas. S-E. Al-Batran: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: SERVIER; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Celgene; Speaker Bureau / Expert testimony: Nordic Bioscience ; Research grant / Funding (institution): Hospira; Research grant / Funding (institution): Medac; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Roche Pharma AG; Research grant / Funding (institution): Vifor Pharma. Y-J. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genetech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy: Taiho; Advisory / Consultancy, Research grant / Funding (institution): Daiich-Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Advisory / Consultancy, Research grant / Funding (institution): GreenCross; Advisory / Consultancy: Samyang Biopharm; Advisory / Consultancy: Hanmi; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Boston Biomedical. D. Catenacci: Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Gritstone; Honoraria (self), Advisory / Consultancy: Taiho; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Daichii Sankyo. P. Enzinger: Advisory / Consultancy: Merck; Advisory / Consultancy: Astellas; Advisory / Consultancy: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: Loxo; Advisory / Consultancy: Taiho. D. Ilson: Honoraria (self): Astellas. S. Kim: Advisory / Consultancy: Astellas. F. Lordick: Advisory / Consultancy: Astellas; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: AstraZeneca. K. Shitara: Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Takeda; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): Novartis; Honoraria (self): AbbVie; Honoraria (self): Yakult; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Chugai Pharma; Advisory / Consultancy, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Medi Science. E. Van Cutsem: Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy: Incyte; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Ipsen. A. Arozullah: Full / Part-time employment: Astellas. J. Wook Park: Full / Part-time employment: Astellas Pharma Global Development Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.